# Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

> **NCT01428219** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT01428219
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2014-10
- **Final completion:** 2015-09
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Closed due to slowing enrollment and negative results of a phase III trial using cabozantinib.
- **Last updated:** 2017-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428219, "Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01428219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*